Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04092738
Other study ID # PI17/01788
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 4, 2019
Est. completion date September 2021

Study information

Verified date September 2019
Source Jordi Gol i Gurina Foundation
Contact Anna Puig-Ribera
Phone +34 619352497
Email annam.puig@uvic.cat
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of the study is measuring the impact of a ´sit less, move more` mHealth intervention at work on the glycaemic control and anthropometric profile of office employees with diabetes type 2 (DT2) at short, mid and long term.


Description:

A double-blind randomized controlled trial. Seven Primary Care Centers from Spain (n=5 Catalonia, n=2 Madrid), 2 hospitals (n=1 Catalonia, n=1 Madrid) and 2 companies (occupational health services; n=1 public, n=1 private) will participate in the study. In each center, physicians, nurses, endocrinologists and occupational physicians will recruit patients with DT2 who spend at least 55% of their working hours doing desk-based tasks (OSPAQ) and have a cellphone. Following the CONSORT Statement (2010), volunteers will be randomized into a control (CG) or intervention group (IG) by the research team using a computer program to generate the random sequence. 184 individuals are needed in each group. Main variables: fasting glucose levels, HbA1c, weight, height, BMI, waist circumference. Occupational sitting time and sitting time breaks will be measured using ActivPAL devices. Other variables: physical activity (IPAQ short), quality of life (EuroQool), presenteeism (WLQ), triglycerides, total cholesterol (LDL and HDL), blood pressure and sociodemographic variables.

Intervention: A mHealth program (13 wks) will progressively replace occupational sitting time with light physical activities. Participants from the CG will receive usual care. Multivariate analysis will assess changes over time (post intervention and at 6 months follow up) in the dependent variables; looking at differences between groups. Intention to treat will be applied.


Recruitment information / eligibility

Status Recruiting
Enrollment 368
Est. completion date September 2021
Est. primary completion date January 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- DM2 diagnosed office employees according to international criteria.

- Doing sedentary tasks during at least a 55% of their daily work schedule (according to the Occupational Sedentary and Physical Activity Questionnaire: OSPAQ >55%).

- Having a cellphone .

- Having a minimum work contract of 18.5 hours per week.

- Being able to get up from the chair or to walk by themselves (without any help).

Exclusion Criteria:

- Not having a cellphone.

- Having some pathology/disability/injury which changes their ability and capacity to walk or getting up from the chair.

- Doing less than a 55% of the daily tasks in a sitting position according to the OSPAQ questionnaire.

Study Design


Intervention

Behavioral:
Walk@WorkApp-Diab
The intervention (Walk@WorkApp-Diab), based on an mHealth program, consists on replacing sedentary job tasks for active ones, during 13 weeks. The intervention group will download the mHealth program into their personal cellphones

Locations

Country Name City State
Spain IDIAP Jordi Gol Barcelona

Sponsors (6)

Lead Sponsor Collaborator
Jordi Gol i Gurina Foundation Consorci Hospitalari de Vic, Institut Català de la Salut, Instituto de Salud Carlos III, Puerta de Hierro University Hospital, University of Vic - Central University of Catalonia

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Other Change in health-related quality of life EQ-5d-3L. Scores range from 0 to 100 (0 describes the worse health you can imagine while 100 describes the best health you can imagine) Three measurment points: (a) before the intervention, (b) immediately after the intervention, (c) at 6 months after the intervention has finished.
Other Change in Presenteeism levels Work Limitations Questionnaire. Scores range from 0 to 100 (0 describes that your health dones not limit you at all in doing thw work tasks, while 100 describes your health limits you a lot your work tasks) Three measurment points: (a) before the intervention, (b) immediately after the intervention, (c) at 6 months after the intervention has finished.
Other Change in concentration of Triglycerides Blood tests (mg/dL) Two measurement points: (a) Before the intervention starts, (b) at 6 months after the intervention has finished.
Other Change in total cholesterol levels Blood tests (mg/dL) Two measurement points: (a) Before the intervention starts, (b) at 6 months after the intervention has finished.
Other Change in blood pressure Digital automatic blood pressure monitor—Omron M7 (mmHg) Three measurment points: (a) before the intervention, (b) immediately after the intervention, (c) at 6 months after the intervention has finished.
Other Sociodemographic variables (age, gender, socio economic status) Questionnaire One measurment point: (a) before the intervention.
Primary Change in Fasting glucose levels Blood tests Two measurement points: (a) Before the intervention starts, (b) at 6 months after intervention has finished
Primary Change in concentration of HbA1c Blood tests Two measurement points: (a) before the intervention starts, (b) at 6 months after intervention has finished.
Primary Change in weight Body weight in kilograms (electronic scale—Seca 899/217) Three measurement points: (a) before the intervention, (b) immediately after the intervention, (c) at 6 months after intervention has finished.
Primary Change in height Body height in metres (electronic scale—Seca 899/217) Three measurement points: (a) before the intervention, (b) immediately after the intervention, (c) at 6 months after intervention has finished.
Primary Change in Body Mass Index Weight and height will be combined to report Body Mass Index (kg/m2) Three measurement points: (a) before the intervention, (b) immediately after the intervention, (c) at 6 months after intervention has finished.
Primary Change in Waist circumference Waist circumference in centimetres using a flexible steel tape (Seca 203) Three measurment points: (a) before the intervention, (b) immediately after the intervention, (c) at 6 months after the intervention has finished
Secondary Change in objective Occupational sedentary behaviour Total sitting time (minutes/day), sedendary bouts (daily time spent sitting on less than 20 minutes periods, between 20-60 minutes periods, more than 60 minutes period (ActivPal device) Three measurment points: (a) before the intervention, (b) immediately after the intervention, (c) at 6 months after the intervention has finished.
Secondary Change in subjective domain-specific sedentary behaviour Workforce Sitting Questionnaire (daily time spent sitting watching TV, working, at home, as transport and for leisure during working days and nonworking days (minutes/day) Three measurment points: (a) before the intervention, (b) immediately after the intervention, (c) at 6 months after the intervention has finished.
Secondary Change in objective occupational physical activity Minutes/day spent doing light and moderate-to-vigorous physical activity (ActivPal device) Three measurment points: (a) before the intervention, (b) immediately after the intervention, (c) at 6 months after the intervention has finished.
Secondary Change in subjective occupational physical activity Minutes/day walking, doing moderate and vigorous physical activity (International Physical Activity Questionnaire, IPAQ) Three measurment points: (a) before the intervention, (b) immediately after the intervention, (c) at 6 months after the intervention has finished.
See also
  Status Clinical Trial Phase
Completed NCT03596177 - A Study to Evaluate the Effect of MEDI0382 on Energy Balance in Overweight and Obese Participants With Type 2 Diabetes Mellitus Phase 2
Completed NCT01728740 - Bioequivalence Study for Acarbose / Metformin FDC Phase 1
Completed NCT02648854 - Investigate the Effect of Food on the Pharmacokinetic Characteristics of CKD-395 in Healthy Male Volunteers Phase 1
Recruiting NCT02347020 - Impact of Sleep and Meal Timing on Food Intake Regulation N/A
Completed NCT00577590 - Effects of Fatty Acid Delivery on Heart Metabolism and Function in Type 2 Diabetes (T2DM N/A
Completed NCT00094796 - Rosiglitazone to Reverse Metabolic Defects in Diabetes Phase 2
Completed NCT04830969 - Impact of Periodontal Therapy on Patients With Diabetes Phase 2
Completed NCT03112382 - Effect of SLC30A8 rs13266634 Genetic Polymorphism on Zinc Supplementation and Glycemic Control in Egyptian Patients With Type 2 Diabetes Mellitus Phase 4
Recruiting NCT01197092 - The Effects of a Regenerative Mitochondrial Medication on Physiological Parameters in Case of Diabetes Mellitus Type II Phase 2
Completed NCT00649909 - Effect of Glucose Control on the Response to Aspirin in Type 2 Diabetic Patients N/A
Terminated NCT00554697 - Diabetes Mellitus Type II and Tissue Oxygenation N/A
Not yet recruiting NCT05957224 - Differences in Postprandial Glucose Changes N/A
Active, not recruiting NCT02088658 - Technology Intensified Diabetes Education Study in African Americans N/A
Completed NCT00081328 - Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Phase 3
Completed NCT00482079 - A Study of MK0431 in Patients With Type 2 Diabetes (0431-010) Phase 2
Completed NCT03012074 - Episodic to Real-Time Care in Diabetes Self-Management N/A
Completed NCT02175537 - Microclinic Social Induction Pilot Intervention for Diabetes and Obesity Management in Qatar N/A
Completed NCT01651065 - Micro-Clinic Obesity and Metabolic Risk Prevention Program N/A
Completed NCT00528918 - Comparison of Apidra to Regular Insulin in Hospitalized Patients N/A
Completed NCT00086515 - Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED) Phase 3